For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
The ‘reproducibility crisis’ has highlighted the fact that many life science experiments cannot be replicated and that the conclusions based on these studies may be unfounded, with antibodies identified as an essential part of the problem1-7. Across biomedical research, global annual losses from using poorly characterized antibodies have been estimated at $800 million, not counting wasted research time and resources as well as the impact of false conclusions4.
Recombinant antibodies are developed from a unique set of genes, which removes the variability associated with the production of different antibody batches and thus allows for the generation of reproducible results for research longevity. This long-term assurance of recombinant reagent performance could aid in the translation of research discoveries to diagnostic or drug development pipelines while protecting against any potential delays in time or cost, arising due to batch-to-batch reproducibility.
In this white paper, we demonstrate high reproducibility between different batches of the recombinant anti-PD-L1 antibody [28-8] (ab205921) tested in four different applications, such as IHC, ICC, flow cytometry, and western blot. See the data for yourself by downloading the white paper.